<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3876277/" ref="ordinalpos=3532&amp;ncbi_uid=5641774&amp;link_uid=PMC3876277" image-link="/pmc/articles/PMC3876277/figure/F1/" class="imagepopup">Figure 1.  From: Preclinical Activity of the Rational Combination of Selumetinib (AZD6244) in Combination with Vorinostat in KRAS-Mutant Colorectal Cancer Models. </a></div><br /><div class="p4l_captionBody">Pathway analysis of CRC cell lines at baseline and after treatment with vorinostat, selumetinib, or the combination. A, top 5 pathways enriched in the vorinostat-resistant cell lines (HT29 and SW480) after vorinostat treatment. B, heatmap of the core genes in the HDAC and MAP kinase signaling pathway at baseline, after treatment with vorinostat, selumetinib, and the combination. Pathway diagram derived from BioCarta where the core genes are circled. Red and green in the heatmap represent gene overexpression and underexpression, respectively. C, pathway diagram derived from BioCarta where the core genes are colored in red.</div></div>